Andere talen InflaRx N.V.

Aandelen

IFRX

NL0012661870

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,62 ^USD	-2,99%		+10,96%	-0,61%

24/06	Sectorupdate: Gezondheidszorgaandelen stijgen maandagmiddag	MT
24/06	Sectorupdate: Gezondheidszorg	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Sector Update: Health Care Stocks Advance Monday Afternoon	24/06
Sector Update: Health Care	24/06
InflaRx Anti-Inflammatory Drug Chosen for Phase 2 Acute Respiratory Distress Syndrome Trial; Shares Rise	24/06
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)	24/06
Inflarx?S Gohibic (Vilobelimab) Selected for First Barda-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome	24/06
InflaRx Hosts R&D Event Highlighting the Promise of INF904	05/06
InflaRx N.V. Hosts R&D Event Highlighting the Promise of INF904	05/06
InflaRx N : INF904 R&D Event	05/06
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators	21/05
InflaRx N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update	08/05
InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024	30/04
InflaRx N : 20240425_Minutes 2024 AGM - InflaRx NV_signed	26/04
InflaRx N : Deed of Amendment to the Articles of Association, dated April 25, 2024 - Form 6-K	25/04
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event	24/04
InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
InflaRx N : News Conference Call March 2024	21/03
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans	21/03
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024	19/03
InflaRx Appoints Jan Medina as Head of Investor Relations	22/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen InflaRx N.V.

Aandelen

IFRX

NL0012661870

Andere talen

Filters